In today’s fast-paced healthcare environment, doctors face the daily challenge of navigating vast amounts of medical knowledge to make the right decisions quickly. German healthtech company AMBOSS, founded by physicians, is changing that by delivering real-time. Evidence-based guidance at the point of care — and it’s now gearing up for a major global expansion.
AMBOSS has raised a massive €240 million in fresh financing to accelerate its growth. New long-term investors KIRKBI, M&G Investments, and Lightrock led the round, alongside support from existing backers. This significant capital injection will help AMBOSS expand into new markets and broaden its reach beyond doctors. Empowering nurses and allied health professionals with the same trusted medical knowledge.
With this milestone, AMBOSS has also transitioned into a European stock corporation (SE). A strategic move that positions it for sustainable global growth while ensuring compliance across borders. The structure also sets the stage for a potential initial public offering (IPO) in the future.
Launched in 2012 by physicians Ehsan Khaljani, Madjid Salimi, Benedikt Hochkirchen, and Sievert Weiss, AMBOSS began as a digital tool to help medical students learn smarter. Over time, it has evolved into a comprehensive clinical decision support platform trusted by more than 1 million healthcare professionals across 180 countries.
Combining peer-reviewed medical content with cutting-edge AI, AMBOSS delivers fast, actionable insights that support diagnostics and treatment — right when doctors need it most. Its interactive features — like flowcharts, acute management checklists, and diagnostic pathways — help clinicians tackle complex cases with confidence.
Behind this success is AMBOSS’s unique blend of medical and tech expertise. With a team of 500+ employees — including 150 physicians, scientists, and software engineers — the company continues to bridge the gap between clinical knowledge and technology.
With new funding secured, AMBOSS plans to widen its impact. Its next chapter will focus on equipping nurses, allied health professionals, and other healthcare workers with the same high-quality resources. This expansion aligns with AMBOSS’s mission to improve patient care by empowering every healthcare professional involved in decision-making.
In the U.S., AMBOSS has already become an essential resource for medical students and residents. Reports show 25% of first-year U.S. residents now rely on the platform for clinical decisions during their critical transition into practice. In Germany, one out of every two inpatient treatments is guided by a physician using AMBOSS.
Artificial intelligence is central to AMBOSS’s platform — but the company takes a responsible AI approach, ensuring accuracy, safety, and ethical use. Its AI distills vast medical databases into precise recommendations that align with the latest clinical guidelines. This helps reduce diagnostic errors while saving valuable time during patient care.
AMBOSS’s focus on trustworthy AI strengthens its position as a digital co-pilot for clinicians — enhancing care delivery without replacing human expertise.
This latest funding also strengthens AMBOSS’s M&A strategy. Recent acquisitions include Novaheal, a nursing education platform, and NEJM Knowledge+, a U.S.-based board exam prep tool. Both deals extend AMBOSS’s reach into critical areas of healthcare education.
Co-CEO Benedikt Hochkirchen confirmed the company’s ambition: “We’ve brought on investors committed to our long-term vision. Many manage evergreen funds and will support us through a potential IPO and beyond. This funding allows us to invest further in technology, explore new markets, and continue acquiring companies that align with our mission.”
Co-founder Dr. Madjid Salimi added: “Technology won’t replace healthcare professionals — but those who embrace it will lead. We’re here to ensure they have the best tools possible.”
Long-term investor KIRKBI also sees AMBOSS as a future global leader. “AMBOSS has become a critical platform for both medical students and professionals. We’re thrilled to back their mission of empowering healthcare providers worldwide,” said Peter Bason, Head of Private Capital at KIRKBI.
With its growing global footprint and a sharp focus on innovation, AMBOSS is ready to redefine how medical knowledge is accessed and applied — shaping the future of digital healthcare on a global scale.
